Abstract:1086 Objectives: In this study, arginine-arginine-leucine (RRL) a tumor targeting peptide is designed to link the bifunctional chelator mercaptoacetyltriglycine (MAG3), aiming to explore the labeling conditions of Tc-99m and to evaluate the imaging of this probe in vivo. Methods: Tc-99m was labeled through the SnCl2 reduction method, and the main factors affecting the labeling were investigated respectively to obtain the suitable labeling conditions. The paper chromatography was used to determine the labeling rate and radiochemical purity. Cysteine replacement experiment and incubation experiment of normal saline/bovine serum albumin was utilized to evaluate the stability of Tc-99m-MAG3-RRL in vitro. HepG2 tumor-bearing models were established and after tail vein injection, gamma camera imaging and biodistribution study were respectively performed periodically. Results: The purity of MAG3-RRL was 98.94%. Under the suitable labeling conditions, the labeling rate was 93.67% ± 1.10%, and the radiochemical purity was 94.32% ± 0.19% (n=3). Tc-99m-MAG3-RRL was placed in normal saline at room temperature and 50% BSA at 37 ℃, the radiochemical purity of Tc-99m-MAG3-RRL was more than 90% (n=3) within 6 hours. The highest replacement rate of Tc-99m-MAG3-RRL was 0.57% ± 0.21% in cysteine solution, and 0.41% ± 0.04% in normal saline control (n=3, P>0.05). The distribution coefficient IgP of Tc-99m-MAG3-RRL was -0.15 ± 0.01 (n=3). Gamma camera imaging revealed substantial uptake of Tc-99m-MAG3-RRL in tumors. The specific uptake of Tc-99m-MAG3-RRL in tumor was significantly higher than that of control test after injection (P<0.05). In planar gamma imaging study, the tumors were imaged clearly at 2-4h after injection of Tc-99m-MAG3-RRL, with the highest tumor-to-muscle ratio 5.63 ± 0.40 in 30min. Biodistribution data showed that Tc-99m-MAG3-RRL was rapidly accumulated in tumor within 30min with the highest tumor-to-muscle ratio 5.50 ± 0.74. And then it was rapidly cleared from the blood and predominantly accumulated in the kidneys. Conclusions: The results show that MAG3 could successfully be connected to RRL polypeptide and further improve the labeling rate, and the preparation method of Tc-99m-MAG3-RRL is simple and fast. Tc-99m-MAG3-RRL probe has good stability in vitro. Animal study shows that Tc-99m-MAG3-RRL can be used as a potential candidate for visualization of malignant carcinomas. Keywords: Arginine-Arginine-Leucine; Tc-99m; MAG3

Study on pharmacokinetics and acute toxicity of new molecular probe 99 m Tc-RRL

Detection of Pulmonary Metastases with the Novel Radiolabeled Molecular Probe, (99M)tc-Rrl.

A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

Study of Novel Peptide Probe 131 I-RRL for Tumor Molecular Imaging

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

A novel radioiodinated peptide of arginine-arginine-leucine(RRL)for biodistribution and tumor angiogenic endothelium imaging

Technetium-99m- Arg-Arg-Leu(g2), a Modified Peptide Probe Targeted to Neovascularization in Molecular Tumor Imaging.

The Further Study on Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovascularization As Well As Tumor Cells in Molecular Tumor Imaging

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Study on Pharmacokinetics and Acute Toxicity of Human Telomerase Reverse Transcriptase Antisense Oligonucleotide Molecular Probe

Preparation and experimental study of a new renal imaging agent: N, N-BIS (2-aminoethyl) propane haxaacetic acid labeled with technitium-99m

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

A Novel Tc-99m-labeled and MAG<sub>3</sub>-chelated Arginine-Arginine-Leucine containing Peptide for Tumor Imaging in Hepatoma Xenografts Model

Synthesis, Biodistribution and Quantitative Structure-Activity Relationship Studies of New 99mtc Labeled Pseudo-Peptide Complexes.

Potential Therapeutic Radiotracers: Preparation, Biodistribution and Metabolic Characteristics of 177 Lu-labeled Cyclic RGDfK Dimer

99Tcmn-Dgdtc,a New Glucose Metabolic Agent,the Pharmacokinetics and Imaging Results

Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis

Pharmacokinetics and Radiation Dosimetry of Tc-99m-3prgd(2) in Healthy Individuals: A Pilot Study

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Arginine-Arginine-Leucine Peptide Targeting Heat Shock Protein 70 for Cancer Imaging

Noninvasive PET Imaging of a Ga-68-Radiolabeled RRL-Derived Peptide in Hepatocarcinoma Murine Models